Dr. Steve Felstead, MB-ChB, is Chief Medical Officer at Juvenescence. He is also Managing Director of Deljay Consulting Limited, providing services to Pharma, Biotech, and Venture Capital industries.

“The science of longevity is endlessly fascinating,” he says, “The possibilities to impact people’s lives with our research drives us all here.”

Dr. Felstead was Vice President, Head of Clinical Research in the pharmatherapeutics division at Pfizer Inc., in both the UK and the US. Steve was responsible for clinical development and pharmacology, translational and molecular medicine, preclinical and clinical statistics. He led the team that laid the groundwork for the NIH/NCATS program for systematic evaluation of drug repurposing. In addition to his line management and senior leadership roles, Dr. Felstead was involved in multiple projects, as member and team leader, helping to develop Zithromax (azithromycin), Viagra (sildenafil), and Vfend (voriconazole). Dr. Felstead led the Viagra (sildenafil) team when the first pulmonary hypertension study was being designed, which led to the successful Revatio development program. He also led the Celsentri/Selzentry (maraviroc) team through to successful transatlantic registration of this novel anti-retroviral medicine.  

Dr. Felstead is a member of AdALta Limited’s Scientific Advisory Board, a Non-executive director for MGB Biopharma Ltd, CMO for Mironid Limited, and a member of TRICAPITAL Business Angel group, which invests in emerging businesses in the Scottish Borders. Dr. Felstead served as member of Innovate UK’s Biomedical Catalyst Late Stage Award committee from 2014-2019, and served as CMO for Mironid Limited from 2019-2022.

If all of the above isn’t enough to keep Steve passionate about keeping life interesting, he is currently teaching himself to play guitar.

Steve Felstead has a Bachelor of Medicine and Surgery degree from Leeds University in the UK.